Study S001895

Effect of Liraglutide on Vascular Inflammation in Type-2 Diabetes: A Randomized, Placebo-controlled, Double-blind, Parallel Clinical PET/CT Trial The Liraflame Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT03449654
Acronym: LIRAFLAME
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: DOUBLE
Status: COMPLETED
Enrollment: 102
Start: 2017-10-26
Primary completion: 2019-08-16
Lead sponsor: Steno Diabetes Center Copenhagen
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Liraglutide; DRUG:Placebo (for liraglutide)
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Change in vascular inflammation [baseline to week 26]

Linked records (5)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0048817	Ceramides are decreased after liraglutide treatment in people with type 2 diabetes: a post hoc analysis of two randomized clinical trials Wretlind, Asger, Figshare	2024	Randomized trial	DOI	cites ClinicalTrials.gov:NCT03449654
R0007317	Ceramides are decreased after liraglutide treatment in people with type 2 diabetes: a post hoc analysis of two randomized clinical trials. Wretlind A, Lipids in health and disease	2023	Randomized trial	PMID 37752566 DOI	cites ClinicalTrials.gov:NCT03449654; registry reference DERIVED:37752566
R0017102	Liraglutide Lowers Palmitoleate Levels in Type 2 Diabetes. A Post Hoc Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial. Wretlind A, Frontiers in clinical diabetes and healthcare	2022	Randomized trial	PMID 36992761 DOI	cites ClinicalTrials.gov:NCT03449654; registry reference DERIVED:36992761
R0008541	Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial. Zobel EH, BMJ open diabetes research & care	2021	Randomized trial	PMID 34518158 DOI	cites ClinicalTrials.gov:NCT03449654; registry reference DERIVED:34518158
R0010519	Effect of Liraglutide on Arterial Inflammation Assessed as [18F]FDG Uptake in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. Ripa RS, Circulation. Cardiovascular imaging	2021	Randomized trial	PMID 34187185 DOI	cites ClinicalTrials.gov:NCT03449654; registry reference DERIVED:34187185